Johnson & Johnson's ₹100 Crore Drink Blocked! Court Delivers Shocking Verdict on ORSL

CONSUMER-PRODUCTS
Whalesbook Logo
AuthorSatyam Jha|Published at:
Johnson & Johnson's ₹100 Crore Drink Blocked! Court Delivers Shocking Verdict on ORSL
Overview

The Delhi High Court has refused to grant interim relief to JNTL Consumer Health, the Indian subsidiary of Johnson & Johnson, allowing them to sell their ORSL Electrolyte Drink. The ban, stemming from FSSAI directives against misleading ORS labels, affects nearly ₹100 crore worth of unsold stock. The court expressed concerns that consumers suffering from diarrhea might be misled.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

The Delhi High Court, through a Division Bench comprising Chief Justice Devendra Kumar Upadhyaya and Justice Tushar Rao Gedela, has denied an interim order that would have permitted JNTL Consumer Health, Johnson & Johnson's Indian arm, to sell its ORSL Electrolyte Drink. This decision follows a directive from the Food Safety and Standards Authority of India (FSSAI) that bans beverages with misleading Oral Rehydration Solution (ORS) labels. The company has approximately ₹100 crores worth of ORSL stock currently unsold.

The court expressed concern that individuals suffering from diarrhea, who typically seek ORS to rebalance electrolytes, might be misled into purchasing JNTL's product, which is advertised as an 'energy drink with electrolytes'. This ruling comes after a single-judge bench also refused to interfere with the FSSAI orders, which were initially challenged by Dr. Reddy's Laboratories.

JNTL Consumer Health had filed a plea challenging the FSSAI's directives issued on October 14, 15, and 30, along with Regulation 5 of the Food Safety and Standards (Food Recall Procedure) Regulations, 2017. Their senior counsels argued that the product has been in the market for over two decades without any complaints of adulteration, and they have already ceased manufacturing, planning to rebrand the product. They stressed that treating the ₹100 crore stock as an adulterated drug would be unfair.

However, the court remained unconvinced by these arguments and rejected the plea for interim relief.

Impact
This ruling directly impacts Johnson & Johnson's Indian operations by preventing the sale of a significant stock of their product, potentially leading to financial losses and necessitating a re-evaluation of their marketing and labeling strategies in India. It also highlights the stringent regulatory environment for health and consumer products in the country.
Rating: 6/10

Difficult Terms:
Interim Orders: Temporary orders issued by a court before a final judgment is made.
Subsidiary: A company controlled by a holding company.
Food Safety and Standards Authority of India (FSSAI): The statutory body responsible for protecting and promoting public health through regulation and supervision of food safety in India.
Oral Rehydration Solution (ORS): A mixture of salts and glucose used to treat dehydration, especially that due to diarrhea.
Misleading Labels: Labels that convey false or deceptive information about a product.
Division Bench: A panel of two or more judges of a court.
Adulterated: Lowered in quality by adding inferior or harmful substances.
Regulation: A rule or directive made and maintained by an authority.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.